ストックスクリーナーアプリを入手
7.00
0.00%
0.00
アフターアワーズ：
7.31
0.31
+4.43%
前日終値:
$7.00
開ける：
$7.1
24時間の取引高:
139.94K
Relative Volume:
1.63
時価総額：
$61.11M
収益：
$123.24M
当期純損益:
$136.00K
株価収益率:
-350.00
EPS:
-0.02
ネットキャッシュフロー:
$-148.99M
1週間 パフォーマンス:
-3.18%
1か月 パフォーマンス:
-27.31%
6か月 パフォーマンス:
-60.08%
1年 パフォーマンス:
-67.59%
1日の値動き範囲:
$6.99
$7.41
1週間の範囲:
$6.73
$7.41
52週間の値動き範囲:
$6.53
$30.60
Seres Therapeutics Inc Stock (MCRB) Company Profile
名前
Seres Therapeutics Inc
セクター
電話
617 945 9626
住所
200 SIDNEY STREET, CAMBRIDGE, MA
MCRB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
7.00 | 63.14M | 123.24M | 136.00K | -148.99M | -0.02 |
|
ONC
Beone Medicines Ltd Adr
|
251.72 | 25.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.48 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3401 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.81 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.86 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-08 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-04-21 | 開始されました | JP Morgan | Neutral |
| 2021-07-23 | ダウングレード | Goldman | Neutral → Sell |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-03-05 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-11 | アップグレード | Jefferies | Hold → Buy |
| 2019-04-30 | 開始されました | Jefferies | Hold |
| 2018-10-22 | 開始されました | Chardan Capital Markets | Buy |
| 2017-10-13 | 開始されました | Oppenheimer | Outperform |
| 2017-08-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-02-01 | 繰り返されました | FBR & Co. | Outperform |
| 2016-08-12 | 繰り返されました | FBR Capital | Outperform |
| 2016-08-01 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-07-29 | 再開されました | H.C. Wainwright | Buy |
| 2016-03-30 | 開始されました | FBR Capital | Outperform |
| 2016-03-03 | 開始されました | Guggenheim | Buy |
| 2016-01-25 | 開始されました | H.C. Wainwright | Buy |
| 2015-10-22 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 開始されました | Canaccord Genuity | Buy |
| 2015-07-21 | 開始されました | Goldman | Neutral |
| 2015-07-21 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Seres Therapeutics Inc (MCRB) 最新ニュース
Denodo University Challenge Now Open: Data and AI for Real-World Impact - GlobeNewswire Inc.
5 Best Microbiome Companies (June 2025) - Securities.io
Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of “Reduce” by Brokerages - Defense World
Seres Therapeutics reports promising biomarker data By Investing.com - Investing.com South Africa
Seres Therapeutics (MCRB) to Present New Biomarker Data at ASCO 2025 | MCRB Stock News - GuruFocus
Seres Therapeutics reports promising biomarker data - Investing.com
Seres Therapeutics to Present New Biomarker Data from SER-155 Phase 1b Study at 2025 ASCO Annual Meeting - Nasdaq
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting - The Manila Times
Breakthrough: Seres Therapy Cuts Deadly Infection Risk by 77% in Cancer Transplant Patients, ASCO Data Shows - Stock Titan
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - Defense World
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade - NewsBreak: Local News & Alerts
Human Microbiome Market Forecast: Growth Trends, Key Players & - openPR.com
Seres Therapeutics’ (MCRB) “Neutral” Rating Reiterated at Chardan Capital - Defense World
StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold - Defense World
Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25 - marketscreener.com
MCRB: Seres Therapeutics' Price Target Raised by Chardan Capital | MCRB Stock News - GuruFocus
Chardan cuts Seres Therapeutics stock rating to neutral - Investing.com
Seres Therapeutics: Q1 Earnings Snapshot - Norwalk Hour
Seres Therapeutics Reports Positive Q1 2025 Results - TipRanks
Seres Therapeutics’ Positive Earnings Call: Progress and Challenges - TipRanks
Transcript : Seres Therapeutics, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Earnings call transcript: Seres Therapeutics Q1 2025 sees net income boost - Investing.com Nigeria
Seres Therapeutics, Inc. SEC 10-Q Report - TradingView
Seres Therapeutics Advances SER-155 Program with FDA Submission - TipRanks
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics (MCRB) Targets Advancement of SER-155 in Clinical Development | MCRB Stock News - GuruFocus
Seres Therapeutics Inc Qtrly EPS $3.76 - marketscreener.com
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 - The Globe and Mail
Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $80.00 - Defense World
Seres Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com - Defense World
Seres Therapeutics Reveals Game-Changing Biomarkers for IBD Treatment, Seeks Development Partners - Stock Titan
Seres Therapeutics (MCRB) to Unveil New Findings at 2025 Digesti - GuruFocus
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases - The Manila Times
Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Weak at 0.70, Down -2.90 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - Defense World
MCRB Stock Update: Seres Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
Seres Therapeutics Inc (MCRB) expanding its growth trajectory ahead - Sete News
Petri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock split - The Business Journals
Seres Therapeutics Inc (MCRB) 財務データ
収益
当期純利益
現金流量
EPS
Seres Therapeutics Inc (MCRB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Shaff Eric D. | CEO and President |
May 16 '25 |
Sale |
7.28 |
220 |
1,602 |
10,102 |
| DesRosier Thomas | Chief Legal Officer and EVP |
May 15 '25 |
Sale |
7.28 |
79 |
575 |
7,287 |
| Henn Matthew R | See Remarks |
May 16 '25 |
Sale |
7.28 |
77 |
561 |
4,383 |
| Young Teresa L. | See Remarks |
Feb 18 '25 |
Sale |
0.81 |
3,338 |
2,704 |
97,536 |
| Henn Matthew R. | See Remarks |
Feb 18 '25 |
Sale |
0.81 |
3,953 |
3,204 |
84,443 |
| Shaff Eric D. | CEO and President |
Feb 18 '25 |
Sale |
0.81 |
12,726 |
10,314 |
192,039 |
| DesRosier Thomas | Chief Legal Officer and EVP |
Feb 18 '25 |
Sale |
0.81 |
4,300 |
3,485 |
142,456 |
| von Moltke Lisa | See Remarks |
Feb 18 '25 |
Sale |
0.81 |
4,416 |
3,579 |
39,875 |
| DesRosier Thomas | Chief Legal Officer and EVP |
Nov 18 '24 |
Sale |
0.54 |
878 |
475 |
135,192 |
| von Moltke Lisa | See Remarks |
Nov 18 '24 |
Sale |
0.54 |
977 |
528 |
32,415 |
0.87%
0.19%
大文字化:
|
ボリューム (24 時間):